ERAS News and Press, Erasca Inc. From 11/10/21

Strong execution leading to four ongoing clinical trials evaluating lead candidates ERAS-007 (ERKi) and ERAS-601 (SHP2i) Named one of Fierce Biotech’s “Fierce 15” most promising biotechnology companies of 2021 Donated $17.5 million of common shares t...

ERAS-801's CNS penetration: four times higher than approved EGFR inhibitors Comprehensive inhibition against oncogenic EGFR vIII and wildtype alterations Improved outcomes in over 90% of EGFR-driven patient-derived glioblastoma models IND submission in refractory gliobla...

Point Roberts, WA and Delta, BC - October 22, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Mining and Cannabis. Today's stocks have been added to our lists of free st...

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Fierce Biotech has name...

A record 62 recent IPOs joined the Russell 2000 small-cap index this month. Here's a look at some of the biotech stocks that just joined: Lyell Immunopharma Lyell Immunopharma (NASDAQ:LYEL), which is developing T cell therapies for solid tumors, had a 25M-share IPO in June expected to net pro...

SAN DIEGO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced dosing of the first patient ...

SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced dosing of the first patient ...

ERAS-007, a potential best-in-class ERK1/2 inhibitor, will be evaluated in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) HERKULES-3 CRC Phase 1b/2 trial initiation expected in H2 2021 SAN DIEGO, Sept. 08, 20...

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Mor...

Erasca (NASDAQ:ERAS): Q2 GAAP EPS of -$1.20 misses by $0.49. Cash and equivalents of $198.7M Press Release For further details see: Erasca Q2 EPS misses by $0.49